ReviewImmune network2018
From Bench to Clinic: the Potential of Therapeutic Targeting of the IL-22 Signaling Pathway in Atopic Dermatitis.
Review in Immune network, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 33 citations in OpenAlex.
- Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial.JAMA dermatology · 2020Trial
- Memory Cells in Atopic Dermatitis: Paving the Way to Disease Modification.International journal of molecular sciences · 2026Review
- Therapeutic Potential and Mechanisms of Mesenchymal Stem Cell and Mesenchymal Stem Cell-Derived Extracellular Vesicles in Atopic Dermatitis.Journal of inflammation research · 2024Review
- IL-22 is secreted by proximal tubule cells and regulates DNA damage response and cell death in acute kidney injury.Kidney international · 2024Article
- Skin barrier-inflammatory pathway is a driver of the psoriasis-atopic dermatitis transition.Frontiers in medicine · 2024Review
- Interplay of cytokines in the pathophysiology of atopic dermatitis: insights from Murin models and human.Frontiers in medicine · 2024Review
- Immunosenescence and Skin: A State of Art of Its Etiopathogenetic Role and Crucial Watershed for Systemic Implications.International journal of molecular sciences · 2023Review
- Multiple Roles for Cytokines in Atopic Dermatitis: From Pathogenic Mediators to Endotype-Specific Biomarkers to Therapeutic Targets.International journal of molecular sciences · 2022Review
- Immunopathology and Immunotherapy of Inflammatory Skin Diseases.Immune network · 2022Review
- The Role of T Helper 22 Cells in Dermatological Disorders.Frontiers in immunology · 2022Review
- Galectin-9 contributes to the pathogenesis of atopic dermatitisFrontiers in immunology · 2022Article
- New Treatments for Atopic Dermatitis Targeting Skin Barrier Repair via the Regulation of FLG Expression.Journal of clinical medicine · 2021Review
- Keratinocytes: innate immune cells in atopic dermatitis.Clinical and experimental immunology · 2021Review
- Immunological Aspects of Skin Aging in Atopic Dermatitis.International journal of molecular sciences · 2021Review
- Vitamin D Inhibits IL-22 Production Through a Repressive Vitamin D Response Element in theFrontiers in immunology · 2021Article
- IL-22 Signaling in the Tumor Microenvironment.Advances in experimental medicine and biology · 2021Article
- IL-17-Producing Cells in Tumor Immunity: Friends or Foes?Immune network · 2020Review
- Local Stabilization of Hypoxia-Inducible Factor-1α Controls Intestinal InflammationFrontiers in immunology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atopic dermatitis (AD) is the most common pruritic inflammatory skin disease characterized by thickening of epidermis and dermis as well as by the infiltration of multiple pathogenic polarized T lymphocytes, including Th2, Th17, and Th22 cells. Significant progress has been made to develop targeted therapeutics for treating AD, e.g., Food and Drug Administration-approved dupilumab, an antibody for dual targeting of IL-4 and IL-13 signaling pathways. Additionally, a growing body of published evidence and a promising result from the early stage of the clinical trial with ILV-094, an anti-IL-22 antibody, strongly support the notion that IL-22 is a potential therapeutic target for treating AD. Moreover, we also experimentally proved that IL-22 contributes to the pathophysiology of AD by employing a murine model of AD induced by epicutaneous sensitization. Here, we review recent preclinical and clinical findings that have advanced our understanding of the roles of IL-22 and Th22 cells in skin inflammation. We conclude that blockade of IL-22 signaling may be a promising therapeutic approach for the treatment of AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.